



PRIMARY RESEARCH

# KOL Perception Study Cardiomyopathies (US)

In-depth KOL Interviews | 25 Respondents | United States

---

**25**

KOL Respondents

**30–45**

Min Interviews

**5**

Specialties



# 01

## STUDY OVERVIEW

### GEOGRAPHY

United States

### RESPONDENTS

25 KOLs

### METHODOLOGY

In-depth Interviews


### DURATION

30–45 Minutes

### STUDY TYPE

Qualitative + Quantitative

## Respondent Profile



# What KOLs Told Us

## 92%


Interested in  
disease-modifying  
therapies

## 96%

Expect precision  
medicine growth

## 88%

Report significant  
unmet need



## Where Gaps Remain

### Delayed Referrals

84% of KOLs

84%

### Low PCP Awareness

80% of KOLs

80%

### Misdiagnosis as HF

76% of KOLs

76%

*" Earlier diagnosis remains a major unmet need across all cardiomyopathy subtypes. "*

## Most Common & Treatment Gaps

### Dilated CM (DCM)

88%



### Hypertrophic CM (HCM)

76%



### ATTR-CM

68%



### Top Unmet Needs

- Disease-Modifying Therapies 92%
- Earlier Diagnosis Tools 84%
- Better Long-Term Outcomes 76%

## Promising Therapies & Quantitative Ratings

# 88%

### Precision Medicine

KOLs rate as most promising

# 80%

### Gene Therapy

High adoption interest

# 76%

### RNA Therapies

Growing evidence base

96% of KOLs expect increased precision medicine use in the next 5 years | 88% anticipate expanded targeted therapy adoption

### Quantitative Ratings (1–5 Scale)

Willingness to Adopt Novel Therapies



Unmet Need



Importance of Genetic Testing



Satisfaction with Current Therapies



# Implications & Next Steps

## 01 Physician Education

Invest in early diagnosis training for PCPs & referring specialists

## 02 Genetic Counseling

Expand access to genetic testing & family screening pathways

## 03 Payer Evidence

Strengthen real-world evidence to address reimbursement barriers

## 04 Referral Pathways

Improve routing to specialty & academic centers

## 05 Outcomes Research

Support long-term data generation for novel therapies



# Thank You

Do you have any questions?

+91-959-915-8047

[info@sperresearch.com](mailto:info@sperresearch.com)

<https://www.sperresearch.com>

Corporate Office:

#303-304, Tower B, Noida One, Sector 62, Noida, India